Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer

Journal of Cancer Research and Therapeutics

Volumn 3, Issue 4, 2007, Pages 207-210

  Aggarwal, Himanshu ^a   Lubana, Parvinder S ^a   Jain, D K ^a   Mathur, R K ^a  

^a MGM MEDICAL COLLEGE   (India)

Author keywords

Apoptosis; Bcl 2; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PROTEIN BCL 2;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 39349111265     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.38995     Document Type: Article

References (15)

1. Paymaster JC. Cancer of the breast in Indian women. Surgery 1956;40:372-7.
2. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998;48:107-16.
3. Kerr JF, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
4. Jussawalla DJ, Yeole BB, Natekar MV, Narayan RA. Epidemiology of breast cancer in India. Indian J Cancer 1975;12:231-42.
5. Poelman SM, Adeyanju MO, Robertson MA, Recant WM, Karrison T, Fleming GF, et al. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res 2000;6:4043-8.
6. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999;6:61-8.
7. Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998;175:127-32.
8. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003;9:33-41.
9. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
10. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer MD: Anderson Cancer Center experience. Surg Oncol Clin North Am 1995;4:715-34.
11. Singh G, Singh DP, Gupta D, Muralikrishna BV. Neoadjuvant chemotherapy in locally advanced breast cancer. J Surg Oncol 1996;61:38-41.
12. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993;11:467-73.
13. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res 2001;99:161-8.
14. Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, et al. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000;83:1380-6.
15. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.